Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Åke Lernmark

Principal investigator

Default user image.

High plasma levels of islet amyloid polypeptide in young with new-onset of type 1 diabetes mellitus.

Author

  • Johan F Paulsson
  • Johnny Ludvigsson
  • Annelie Carlsson
  • Rosaura Casas
  • Gun Forsander
  • Sten Ivarsson
  • Ingrid Kockum
  • Åke Lernmark
  • Claude Marcus
  • Bengt Lindblad
  • Gunilla T Westermark

Summary, in English

Islet amyloid polypeptide (IAPP) is a beta cell hormone secreted together with insulin upon glucose stimulation. IAPP participates in normal glucose regulation, but IAPP is also known for its ability to misfold and form islet amyloid. Amyloid fibrils form through smaller cell toxic intermediates and deposited amyloid disrupts normal islet architecture. Even though IAPP and amyloid formation are much discussed in type 2 diabetes, our aim was to study the significance of IAPP in type 1 diabetes.

Department/s

  • Paediatrics (Lund)
  • Paediatric Endocrinology
  • Diabetes and Celiac Unit
  • Vascular Diseases - Clinical Research
  • EXODIAB: Excellence in Diabetes Research in Sweden

Publishing year

2014

Language

English

Publication/Series

PLoS ONE

Volume

9

Issue

3

Document type

Journal article

Publisher

Public Library of Science

Topic

  • Endocrinology and Diabetes
  • Pediatrics

Status

Published

Research group

  • Paediatric Endocrinology
  • Diabetes and Celiac Unit
  • Vascular Diseases - Clinical Research

ISBN/ISSN/Other

  • ISSN: 1932-6203